We Think That There Are More Issues For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical (SZSE:300937) Than Just Sluggish Earnings
The subdued market reaction suggests that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.'s (SZSE:300937) recent earnings didn't contain any surprises. Our analysis suggests that along w
Pharma Tesco (300937.SZ): Net profit of 9.225 million yuan in the first quarter decreased by 70.84% year-on-year
On April 24, Gelonghui (300937.SZ) released its first quarter report. Operating revenue was 1,237 billion yuan, up 10.29% year on year, net profit was 92.25,500 yuan, down 70.84% year on year. After deducting non-net profit of 6.09 million yuan, down 80.65% year on year, with basic earnings of 0.0964 yuan per share.
Pharma Tesco (300937.SZ): Net profit for 2023 increased by 41.69% to 595.32 million yuan, and plans to pay 10.2.2 yuan
On April 9, Ge Longhui (300937.SZ) announced its 2023 annual report. During the reporting period, the company achieved operating income of 4.430 billion yuan, up 11.62% year on year; net profit attributable to shareholders of listed companies was 595.32 million yuan, up 41.69% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 54.271 million yuan, an increase of 37.40% year on year; basic income per share is 0.62 yuan; it plans to distribute a cash dividend of 2.20 yuan (tax included) for every 10 shares to all shareholders.
Medicago (300937.SZ): Deferred Disclosure of 2023 Annual Report
Medico-Tesco (300937.SZ) announced that the company was originally scheduled to disclose “2023...” on April 9, 2024
Medicago (300937.SZ): Termination of issuance of shares to specific targets and withdrawal of application documents
On February 23, Ge Longhui (300937.SZ) announced that the company held the 20th meeting of the 3rd board of directors and the 13th meeting of the 3rd board of supervisors on February 22, 2024 to review and pass the “Proposal on Termination of Issuance of Shares to Specific Targets and Withdrawal of Application Documents”. Since the company disclosed its plan to issue shares to specific targets, the company's board of directors, management and relevant intermediaries have been actively promoting various tasks. In view of the current complex and changing market environment and changes in external financing policies, etc., and comprehensively considering many factors such as the company's business development plan and capital operation plan, it is relevant
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.'s (SZSE:300937) 26% Cheaper Price Remains In Tune With Revenues
The Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SZSE:300937) share price has fared very poorly over the last month, falling by a substantial 26%. Instead of being rewarded, shareh
Medicago (300937.SZ): The ban on 49.3 million shares issued before the initial launch will be lifted on January 29
On January 25, Ge Longhui (300937.SZ) announced an indicative announcement on the listing and circulation of shares issued before the initial public offering. The shares that have been lifted are shares issued by the company before the initial public offering. The number of shares that have been lifted this time is 49.3 million shares, accounting for 51.5331% of the company's total share capital. The listing and circulation date for the shares whose sale restrictions have been lifted is January 29, 2024 (Monday).
Pharmaceutical Easy Purchase (300937.SZ), the supervisor of Tianwen, reduced his holdings by a total of 1,216,800 shares at the end of the reduction period
Pharmaceutical Easy Purchase (300937.SZ) announced that the period of the company's supervisor Tianwen's holdings reduction plan has expired, and through a centralized bidding method...
Pharmaceutical Easy Purchase (300937.SZ): Tianwen reduced its shares by 1.26% by a total of 1.26%
On November 27, Gelonghui (300937.SZ) announced that it recently received the “Notice Letter on Reducing the Shares of Sichuan Hezong Pharmaceutical Co., Ltd. by a total of 1% and the progress of the reduction” issued by Mr. Tian Wenshu, a shareholder holding at least 5% of the company's shares and supervisor. It was learned that Mr. Tian Wenwen reduced his holdings of the company's shares by a total of 1,203,095 shares through centralized bidding between July 19, 2023 and November 24, 2023. The reduction in shareholding accounts for 1.26% of the company's total share capital.
The specific shareholders of Chengdu Boyuan Singapore Airlines and co-actors of Pharmaceutical E-Buy (300937.SZ) reduced their shares by a total of 1.04%
Pharmaceutical Easy Purchase (300937.SZ) issued an announcement. The company recently received the Chengdu Boyuan Singapore Airlines Venture Capital Fund from a specific shareholder...
[BT Financial Report Instantaneous Analysis] Pharmaceutical Tesco 2023 Quarterly Report: Net profit has increased dramatically, and the out-of-hospital market has become the main growth point
This financial report was announced on 2023-10-27 19:57:42 Pharmaceutical E-Commerce (stock code: 300937) is an enterprise that plays an important role in the pharmaceutical distribution industry, providing drug sales and distribution services to consumers. As health reform policies deepen and people pay more attention to healthy living, the pharmaceutical distribution market has ushered in new development opportunities. Drug E-Buy plays an important role in this industry, providing drug sales and distribution services to consumers. In terms of assets and liabilities, E-Pharma's total assets for the third quarter of 2023 were 1,625 billion yuan, compared to 15 at the end of the previous year.
Pharmaceutical Easy Buy (300937.SZ) released the first three quarter results, net profit of 50,1573 million yuan, an increase of 198.95%
Pharmaceutical Easy Buy (300937.SZ) released its report for the third quarter of 2023, achieving revenue of 32.1 in the first three quarters...
Tesco (300937. SZ) plans to invest 42 million yuan in the Huzhou Jiansu Pharmaceutical Tesco Fund to lay out major medical and health sectors
Tesco (300937.SZ) announced that the company intends to participate in the Huzhou Jiansu Tesco venture capital as a limited partner...
Tesco (300937.SZ): It is proposed to establish a wholly-owned subsidiary, Sichuan Tesco Technology Group
GLONGHUI, Oct. 13丨Tesco Pharmaceutical (300937.SZ) announced that on October 13, 2023, Sichuan Hezong Pharmaceutical Co., Ltd. held the 15th meeting of the 3rd board of directors to deliberate and pass the “Proposal on Investing in Establishing Wholly-owned Subsidiaries”. The board of directors agreed that the company will jointly invest with its wholly-owned subsidiary Chengdu Heshengyi Technology Co., Ltd. to establish a wholly-owned subsidiary, Sichuan Yaoyisheng Technology Group Co., Ltd., based on the needs of business planning and business development. The registered capital is RMB 1177.77.
Even With A 26% Surge, Cautious Investors Are Not Rewarding Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.'s (SZSE:300937) Performance Completely
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SZSE:300937) shares have had a really impressive month, gaining 26% after a shaky period beforehand. The last 30 days bring the annual
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical (SZSE:300937) Shareholders YoY Returns Are Lagging the Company's 303% One-year Earnings Growth
It's been a soft week for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SZSE:300937) shares, which are down 16%. But that doesn't change the reality that over twelve months the stoc
Tesco (300937.SZ): Net profit increased by 540.72% in the first half of the year to 467.177 million yuan
GLONGHUI, August 22丨Tesco (300937.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 2.205 billion yuan, up 25.40% year on year; net profit attributable to shareholders of listed companies was 467.177 million yuan, up 540.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 44.1632 million yuan, up 994.04% year on year; basic earnings per share were 0.49 yuan.
Medicinal Tesco (300937.SZ): Chengdu Boyuan Singapore Airlines and Co-Actors have reduced their shareholding by a total of 1.04%
GLONGHUI, August 11丨Medicinal Tesco (300937.SZ) announced that the company recently received the “Notice on Reducing the Shares of Sichuan Joint Pharmaceutical Tesco Pharmaceutical Co., Ltd. by more than half of the time and progress of holdings reduction” issued by Chengdu Boyuan Singapore Airlines, co-actors, Sichuan Hite Airlines, and Chengdu Boyuan Tianhong. As of August 10, 2023, the shareholders' holdings reduction plan was over half of the time, and a total of 996,200 shares had been reduced through centralized bidding, accounting for 1.04% of the company's total share capital.
Chengdu Boyuan Xinhang, a shareholder of Medicinal Tesco (300937.SZ) and co-actors reduced their holdings by 996,200 shares over half of the holdings reduction period
According to the Zhitong Finance App, Medicinal Tesco (300937.SZ) announced that the company's shareholders, Chengdu Boyuan New Airlines, the co-actors, Sichuan Hite Airlines, and Chengdu Boyuan Tianhong have already halfway through the plan to reduce their holdings, totaling 996,200 shares of the company's shares.
Medicinal Tesco (300937.SZ): The current pharmaceutical restructuring will not have an impact on the company
GLONGHUI August 9丨Some investors asked Tesco (300937.SZ), “Did the company's semi-annual performance increase mainly benefit from what factors? Will the ongoing pharmaceutical restructuring have a positive impact on the company?” Medicinal Tesco replied that the company's semi-annual performance growth mainly benefited from the company's business development. The company has disclosed the main reason for the anticipated increase in the current period's performance in the “2023 Semi-Annual Performance Forecast”. The company will disclose the details of the current period's business performance in the 2023 semi-annual report, so stay tuned. The current pharmaceutical restructuring will have no impact on the company.
No Data